Printer Friendly

FOREST LABORATORIES ACQUIRES WORLDWIDE RIGHTS TO DUPONT MERCK PHARMACEUTICAL'S ANTIVIRAL RIMANTADINE

 FOREST LABORATORIES ACQUIRES WORLDWIDE RIGHTS TO DUPONT MERCK
 PHARMACEUTICAL'S ANTIVIRAL RIMANTADINE
 NEW YORK, July 23 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that it had acquired the rights to Rimantadine from Du Pont Merck Pharmaceuticals, Inc. Rimantadine is an antiviral agent used for both the prevention and treatment of influenza A. Financial terms of the transaction were not announced.
 Howard Solomon, president of Forest, stated: "Rimantadine is to be marketed in the U.S. under the tradename Flumadine (R). We consider Flumadine an excellent product opportunity for Forest, which fits in very well with our current marketing activity. It complements Tessalon, our highly successful antitussive product which, incidentally, we also bought from Du Pont. Upon approval, Flumadine will treat an illness which, although varying in virulence from year to year, is nonetheless serious and widespread. According to the Center for Disease Control, ten to fifteen percent of the U.S. population contracts influenza each year.
 Solomon noted: "The new drug application for Flumadine is under review by the Food and Drug Administration. For final approval, it will be necessary for Forest to establish a source for raw material and a manufacturing site. We hope to complete the necessary arrangements and file the necessary data with the FDA by the end of our fiscal year. Depending on the review process at the agency for this limited amount of additional data, we hope Flumadine will be approved in time for the 1994-1995 flu season or possibly earlier. Flumadine is no longer patent protected but will receive five years marketing exclusivity."
 Du Pont Merck is an independent, worldwide pharmaceutical company
established by Du Pont and Merck & Co., Inc. With R&D expenditures exceeding $230 million annually, it is focused on therapies for cardiovascular and central nervous system diseases, oncology, inflammatory diseases, and radiopharmaceuticals.
 -0- 7/23/92
 /CONTACT: Kenneth E. Goodman, vice president-finance of Forest Laboratories, 212-421-7850/
 (FRX) CO: Forest Laboratories Inc. ST: New York IN: MTC SU: TNM


TQ -- NY046 -- 2425 07/23/92 10:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1992
Words:342
Previous Article:THIRD QUARTER EARNINGS OF EZCORP
Next Article:AMETEK'S EARNINGS INCREASE FOR THIRD CONSECUTIVE QUARTER
Topics:


Related Articles
FOREST LABORATORIES ANNOUNCES APPROVAL OF FLUMADINE, A NEW DRUG FOR THE PREVENTION AND TREATMENT OF INFLUENZA A
FRIEDMAN NAMED HEAD OF R&D FOR DUPONT MERCK
THE DUPONT MERCK PHARMACEUTICAL COMPANY FORMS A NEW GENERIC COMPANY, ENDO LABORATORIES L.L.C. AND NAMES CAROL A. AMMON PRESIDENT
DUPONT PHARMA RADIOPHARMACEUTICALS TO ACQUIRE MARKETING ASSETS OF MEDGENIX DIAGNOSTICS RADIOPHARMACEUTICALS IN EUROPE
MITOTIX AND THE DUPONT MERCK PHARMACEUTICAL COMPANY SIGN AGREEMENT TO DEVELOP CELL CYCLE-BASED DRUGS TO TREAT CANCER
BTG Licenses Combination Pain Killing Drug to Forest Laboratories
DuPont Merck and Signal Pharmaceuticals Form Collaboration to Develop Novel Drugs for Hepatitis C and HIV
Merck Acquires SIBIA Neurosciences, Inc., a California-Based Biotechnology Firm; Acquisition Augments Merck's Drug Discovery Program.
DuPont Plans to Acquire CombiChem to Assist in Drug Discovery.
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters